This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Immunomedics Announces Presentations At The 2013 Annual Meeting Of The American Association For Cancer Research

Stocks in this article: IMMU

MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that six posters will be presented at the 2013 Annual Meeting of the American Association for Cancer Research to be held in Washington, DC, from April 6 – 10, 2013.

The schedule and meeting places for the poster sessions, together with the abstract number, poster section and poster board numbers, are listed below:

  • "MAb-PAM4 can differentiate between pancreatic ductal adenocarcinoma and chronic pancreatitis" [Abstract No. 1141, Session Title: Biomarkers 2: Gastrointestinal Cancers, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 1, Poster Board Number 3]  
  • "Targeting interferon-Lambda 1 with a stabilized dimer of anti-tumor Fab" [Abstract No. 1221, Session Title: Cytokines, Modification of the Tumor Microenvironment, and Intervention, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 5, Poster Board Number 1]  
  • "Cell-cell fusion in vivo transfers genes for human malignancy, metastasis, and the donor tumors' organoid phenotype to stromal hamster cells" [Abstract No. 1630, Session Title: Tumor-Stromal Interactions, Monday, April 8, 1:00 p.m. – 5:00 p.m., Hall A-C, Poster Section 21, Poster Board Number 8]  
  • "A Phase I study of IMMU-130 (labetuzumab-SN-38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC)" [Abstract No. LB-159, Session Title: Late-Breaking Research: Clinical Trials, Tuesday, April 9, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 47]  
  • "CD22-targeting epratuzumab mediates trogocytosis of multiple cell-surface markers on normal, malignant, and lupus B cells" [Abstract No. 4744, Session Title: Immune Therapeutics and Monoclonal Antibodies 2, Wednesday, April 10, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 5, Poster Board Number 13]  
  • "Novel T-cell redirecting trivalent bispecific antibodies" [Abstract No. 4747, Session Title: Immune Therapeutics and Monoclonal Antibodies 2, Wednesday, April 10, 8:00 a.m. – 12:00 p.m., Hall A-C, Poster Section 5, Poster Board Number 16]

Cynthia L. Sullivan, President and CEO, commented: "Our presentations represent a diverse set of products and technologies for the therapy of hematological and solid cancers, including our elucidation of the possible mechanism of action of epratuzumab in the therapy of system lupus erythematosus. The late-breaking poster on our IMMU-130 product candidate will present our first clinical results with this novel antibody-drug conjugate in patients with advanced, relapsed, metastatic colorectal cancers from our ongoing Phase I dose-escalation trial."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs